Posted by Michael Wonder on 21 Nov 2018
Roche pulls EU Tecentriq/Avastin filing in kidney cancer
19 November 2018 - Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy.
Roche has opted to withdraw its filing in Europe for a dual regimen for renal cell carcinoma based on checkpoint inhibitor Tecentriq and Avastin, on the grounds that the data supporting it isn’t strong enough.
The combination of PD-L1 inhibitor Tecentriq (atezolizumab) and anti-VEGF drug Avastin (bevacizumab) is at the heart of Roche’s immuno-oncology strategy, but it will have to wait a little longer before it can bring it forward for RCC, the most common form of kidney cancer.
